Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540694 | NSE Symbol : | ISIN : INE236W01016 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
22-May-2025	30-May-2025	Accounts	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 30th May 2025 at 05:30 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business: 1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Any other business that may be necessary with the permission of Chairman.
12-Mar-2025	12-Mar-2025	Change in Other Executives	Pursuant to Regulation 30 of SEBI (LODR), Regulations 2015, the Board of Directors at the meeting held on today March 12, 2025 have considered and appointed Ms. Harshita Aggarwal as the Company Secretary and Compliance Officer of the company w.e.f March 12, 2025.
06-Feb-2025	14-Feb-2025	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results for the Quarter and Nine months ended December 31 2024 along with Limited Review Report. Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 (''Listing Regulations''), this is to inform your that Board of Directors in its meeting held today i.e., February 14, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. (As Per BSE Announcement Dated on: 14/02/2025)
07-Nov-2024	14-Nov-2024	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve 1. To consider and approve the Unaudited Standalone & Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Half year ended 30th September 2024. 2. Transact any other matter if any with permission of chairman. Pursuant to the SEBI [Prohibition of Insider Trading] Regulation and policy on Code of conduct for prevention of Insider Trading and Fair Disclosure of Unpublished Price Sensitive Information of the Company the Trading Window stands closed from 01st October 2024 and will end on 48 hours after the results are made public on 14th November 2024. Pursuant to Regulation 30 of SEBI (LODR), 2015, enclosed are the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on: 14/11/2024)
07-Aug-2024	14-Aug-2024	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Reg. 29 of SEBI (LODR) 2015 it is hereby informed you that the Baord meeting is scheduled to be held on 14th August 2024. Please enclosed herewith BM notice for your reference. Please find and attached herewith enclosed the Outcome of Board Meeting held on today i.e. 14.08.2024 (As per BSE Announcement dated on 14/08/2024)
24-May-2024	30-May-2024	Accounts	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve 1. The Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Any other business that may be necessary with the permission of Chairman. Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended 31st March, 2024. The said Audited Financial Results were reviewed by Audit Committee and thereafter approved by the Board of Directors. Read less.. Financial Result (Standalone & Consolidated) for quarter and year ended as at 31.03.2024 (As Per BSE Announcement Dated on 30.05.2024)
27-May-2024	27-May-2024	Change in Directors	In pursuant to Reg. 30 of SEBI LODR, 2015, The Board of Directors of the company appointed Mr. Harvinder Singh as an Additional Director in the capacity of Independent Director w.e.f. 27.05.2024
07-Feb-2024	14-Feb-2024	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. The Unaudited Standalone & Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended 31st December 2023. 2. Transact any other matter if any with permission of chairman. Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Wednesday, 14th February, 2024 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended on December 31, 2023 along with the Limited Review Report thereon issued by M/s Singh Bhupinder & Associates, Statutory Auditors of the Company. Please find enclosed the Unaudited Financial Results for quarter and nine months ended 31.12.2023. (As Per BSE Announcement Dated on 14/02/2024)
06-Nov-2023	14-Nov-2023	Quarterly Results	Quarterly Results Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, this to submit that the Board of Directors of the company in its meeting held on today i.e. 14th November, 2023, has inter-alia approved the agendas as mentioned in the document herewith enclosed. Standalone & Consolidated Financial Result for quarter and half year ended as at 30.09.2023 (As Per BSE Announcement dated on 14.11.2023)
29-Aug-2023	05-Sep-2023	AGM	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 (LODR) we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday September 5th 2023 at 4:30 PM at the Registered Office of the Company to transact the agendas as mentioned in the enclosed Notice of Board Meeting. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby inform you that the Board of Directors of the Company in its meeting held on today, 05' September, 2023 at its registered office at SCO 113, Darbara Complex, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar, Punjab, 143001, have inter-alia discussed, considered and approved the agendas as mentioned herewith outcome (As Per BSE Announcement Dated on 05.09.2023)
05-Aug-2023	14-Aug-2023	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 (LODR) we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on August 14th 2023 at 4:30 PM at the Registered Office of the Company as mentioned in the attachment With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held on today i.e., 14th August, 2023, have inter- alia, transacted the following item(s) of the Agenda as mentioned in the attachment Financial Result with limited review report for quarter ended as at 30.06.2023 (As Per BSE Announcement Dated on 14.08.2023)
23-May-2023	30-May-2023	Accounts	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Pursuant to reg 29 of the SEBI LODR the meeting of the Board of Directors is scheduled to be held on tuesday 30th May 2023 to consider the matter as enclosed herewith the notice of Board Meeting Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of ANG Lifesciences India Limited at their Meeting held today i.e. Tuesday, May 30, 2023, at the Registered Office of the Company situated at Darbara Complex, SCO- 113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001 transacted the business as per notice dated 23.05.2023. (As Per BSE Announcement dated on 30.05.2023)
28-Mar-2023	05-Apr-2023	Preferential Issue	Pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), we are informing the agendas mentioned herewith disclosure. The next Board meeting will be held on 05' April, 2023 for the purpose of re-consider the issuance of 22,00,000 warrants convertible into equity shares to Promoter Group with subject to the shareholder's approval. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby inform you that the Board of Directors of the Company in its meeting held on today, 05th April, 2023 at its registered office at SCO 113, Darbara Complex, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar, Punjab, 143001, have inter-alia discussed and considered the matters as per document enclosed. (As Per BSE Announcement Dated on 05.04.2023)
27-Feb-2023	06-Mar-2023	Preferential Issue	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/03/2023 inter alia to consider and approve This is to inform you that pursuant to the Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors is scheduled to be held on Monday 06th March 2023 inter-alia to transact the business as per copy enclosed Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby inform you that the Board of Directors of the Company have , considered and approved the following: 1. Increase in Authorised Share Capital of the Company 2. Issue, offer and allot upto 22,00,000 warrants convertible into 22,00,000 Equity Shares of Rs. 10 each on preferential basis to the ANG Capital Investments Private Limited. (Issue price of the Convertible warrants is Rs. 110.00 each. ) 3.Calling an Extra Ordinary General Meeting (EGM) and approved the Notice of Extra Ordinary General Meeting (EGM) of the Members of the Company for EGM to be held on Saturday, 1st April, 2023 at 12:00 P.M. through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM') Means 4. Appointment of M/s. Anjum Goyal & Associates, Practicing Company Secretary as Scrutinizer (As Per BSE Announcement Dated on 06.03.2023) Pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), we are informing the agendas mentioned herewith disclosure. (As per BSE Announcement Dated on 28/03/2023)
06-Feb-2023	14-Feb-2023	Quarterly Results	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 (LODR) we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on February 14th 2023 at 04:30 PM at the Registered Office of the Company to consider and approve the Unaudited Standalone & Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended 31st December 2022 and transact any other matter if any with permission of the Chair. Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Tuesday, 14th February, 2023 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2022 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company. (As Per BSE Announcement Dated on 14.02.2023)

1 2 3

LOGIN HERE

ANG Lifesciences India Ltd

Board Meeting